Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Neprilysin on Glucagon-like Peptide-1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* men~* body mass index between 20-25~Exclusion Criteria:~* acute diseases within the two weeks~* chronic diseases~* smoker~* alcoholism, drug addiction or recent weight loss~* blood donation within the last 3 months

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): No treatment. Participants are subjected to a standardized meal
- Entrestro as single dose (Type: ACTIVE_COMPARATOR): 194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal
- Sitagliptin as single dose (Type: ACTIVE_COMPARATOR): 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
- Entrestro + sitagliptin as single dose (Type: ACTIVE_COMPARATOR): 194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal

Based on this trial design, predict the completion outcome and termination type (if applicable).